Lincoln Financial Group (NYSE: LNC) reported a strong second-quarter performance for 2025, with net income of $688 million, ...

Lincoln National's Q2 beat highlights cost cuts, a Bain Capital stake, and Group Protection growth. Read more for insights on ...

While competitors continue to struggle with healthcare costs, Aetna and CVS are celebrating an 8.4% increase in ...

Lincoln Financial reported strong second-quarter 2025 results that the company said reflects an increasingly diversified earnings mix.

Lincoln Financial Group reported net income of $688 million for the second quarter of 2025, or $3.80 per diluted share, ...

Key Points Non-GAAP earnings per share of $2.36 beat analyst estimates by 25.5% in Q2 2025, while non-GAAP revenue of $4.308 billion missed expectations by 7.6%. The Group Protection segment delivered ...

Lincoln Financial (NYSE: LNC) today reported financial results for the second quarter ended June 30, 2025. Strong performance ...

The Massachusetts Institute of Technology’s Regional Entrepreneurship Acceleration Program (MIT REAP) coaches regions around ...

Here are five finance firms with high Benzinga Edge Value scores that also offer steady dividend yields. Let's take a look.

Offshore reinsurance has increased significantly in the North American life insurance sector, with most reserves ceded to ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.

(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing ...